Top

Published in:

01-11-2009 | Review Article

Actual management of ductal carcinoma in situ of the breast

Authors: Nicolai Maass, Özkan Alkasi, Maret Bauer, Walter Jonat, R. Souchon, Ivo Meinhold-Heerlein

Published in: Archives of Gynecology and Obstetrics | Issue 5/2009

Abstract

Ductal carcinoma in situ (DCIS) represents a premalignant, non-invasive intraductal carcinoma of the breast. About 30% of all mammographically detected breast cancers contain DCIS. Due to the increased use of mammography during the last 20 years the incidence of DCIS has dramatically risen. Histologically it represents a heterogenous group of potentially malignant lesions. The prognosis of DCIS is excellent, but the optimal management of the disease still remains controversial. This review summarizes the results of the latest randomized trials and retrospective analyses investigating the optimal therapeutic strategies in the treatment of DCIS. In addition, it presents a range of treatment options on the basis of the guidelines of the German gynecological oncology group (AGO) 2008.

Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96:906–920PubMedCrossRef

Frykberg ER, Bland KI (1994) Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74:350–361PubMedCrossRef

Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554PubMed

Chan KC, Knox WF, Sinha G et al (2001) Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 91:9–16. doi:10.1002/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO;2-E PubMedCrossRef

Ernster VL, Barclay J, Kerlikowske K et al (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958. doi:10.1001/archinte.160.7.953 PubMedCrossRef

Solin LJ, Kurtz J, Fourquet A et al (1996) Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754–763PubMed

Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000. doi:10.1016/S0140-6736(99)05036-9 PubMedCrossRef

Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95:1692–1702PubMed

MacDonald HR, Silverstein MJ, Mabry H et al (2005) Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 190:521–525. doi:10.1016/j.amjsurg.2005.06.005 PubMedCrossRef

10.

Silverstein MJ, Poller DN, Waisman JR et al (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154–1157PubMedCrossRef

11.

Lagios MD, Silverstein MJ (1997) Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 6:385–392

12.

Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387. doi:10.1200/JCO.2006.06.1366 PubMedCrossRef

13.

Neuschatz AC, DiPetrillo T, Safaii H et al (2001) Margin width as a determinant of local control with and without radiation therapy for ductal carcinoma in situ (DCIS) of the breast. Int J Cancer 96(Suppl):97–104. doi:10.1002/ijc.10357 PubMedCrossRef

14.

Patani N, Cutuli B, Mokbel K (2008) Current management of DCIS: a review. Breast Cancer Res Treat 111:1–10. doi:10.1007/s10549-007-9760-z PubMedCrossRef

15.

Page DL, Dupont WD, Rogers LW et al (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197–1200. doi:10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0 PubMedCrossRef

16.

Silverstein MJ, Lagios MD, Craig PH et al (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267–2274. doi:10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V PubMedCrossRef

17.

Di Saverio S, Catena F, Santini D et al (2008) 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 109:405–416. doi:10.1007/s10549-007-9668-7 PubMedCrossRef

18.

Silverstein MJ, Lagios MD, Groshen S et al (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455–1461. doi:10.1056/NEJM199905133401902 PubMedCrossRef

19.

Wong JS, Kaelin CM, Troyan SL et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24:1031–1036. doi:10.1200/JCO.2005.02.9975 PubMedCrossRef

20.

de Mascarel I, Bonichon F, MacGrogan G et al (2000) Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations. Breast Cancer Res Treat 61:151–159. doi:10.1023/A:1006437902770 PubMedCrossRef

21.

Boland GP, Chan KC, Knox WF et al (2003) Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 90:426–432. doi:10.1002/bjs.4051 PubMedCrossRef

22.

MacAusland SG, Hepel JT, Chong FK et al (2007) An attempt to independently verify the utility of the Van Nuys prognostic index for ductal carcinoma in situ. Cancer 110:2648–2653. doi:10.1002/cncr.23089 PubMedCrossRef

23.

Gilleard O, Goodman A, Cooper M et al (2008) The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 6:61. doi:10.1186/1477-7819-6-61 PubMedCrossRef

24.

Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed

25.

Fisher B, Land S, Mamounas E et al (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28:400–418. doi:10.1016/S0093-7754(01)90133-2 PubMedCrossRef

26.

Houghton J, George WD, Cuzick J et al (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102. doi:10.1016/S0140-6736(03)13859-7 PubMedCrossRef

27.

Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group EORTC Radiotherapy Group. Lancet 355:528–533PubMedCrossRef

28.

Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19:2263–2271PubMed

29.

Daly MB (2006) Tamoxifen in ductal carcinoma in situ. Semin Oncol 33:647–649. doi:10.1053/j.seminoncol.2006.08.019 PubMedCrossRef

30.

Mokbel K (2005) Contemporary treatment of ductal carcinoma in situ of the breast. Med Sci Monit 11:RA86–RA93PubMed

31.

Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A:1425–1427. doi:10.1016/0959-8049(95)00283-O PubMedCrossRef

32.

Schouten van der Velden AP, van Vugt R, Van Dijck JA et al (2007) Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: a population-based study in the East Netherlands. Int J Radiat Oncol Biol Phys 69:703–710PubMed

33.

Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86:429–438. doi:10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y PubMedCrossRef

34.

Neuschatz AC, DiPetrillo T, Steinhoff M et al (2002) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94:1917–1924. doi:10.1002/cncr.10460 PubMedCrossRef

35.

Porembka MR, Abraham RL, Sefko JA et al (2008) Factors associated with lymph node assessment in ductal carcinoma in situ: analysis of 1988–2002 seer data. Ann Surg Oncol 15:2709–2719. doi:10.1245/s10434-008-9947-5 PubMedCrossRef

36.

Cox CE, Nguyen K, Gray RJ et al (2001) Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 67:513–519 (discussion 519–521)PubMed

37.

Cutuli B (2004) Is radiotherapy needed after adequate local excision of localized DCIS? Int J Fertil Womens Med 49:231–236PubMed

38.

Emdin SO, Granstrand B, Ringberg A et al (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45:536–543. doi:10.1080/02841860600681569 PubMedCrossRef

39.

Ringberg A, Nordgren H, Thorstensson S et al (2007) Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast—results from the Swedish randomised trial. Eur J Cancer 43:291–298. doi:10.1016/j.ejca.2006.09.018 PubMedCrossRef

40.

Viani GA, Stefano EJ, Afonso SL et al (2007) Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol 2:28. doi:10.1186/1748-717X-2-28 PubMedCrossRef

41.

Jordan VC (2006) Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. Eur J Cancer 42:2909–2913. doi:10.1016/j.ejca.2006.09.012 PubMedCrossRef

42.

Cutuli B (2000) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: intraductal carcinoma. Cancer 88:1976–1977. doi:10.1002/(SICI)1097-0142(20000415)88:8<1976::AID-CNCR29>3.0.CO;2-P PubMedCrossRef

Title: Actual management of ductal carcinoma in situ of the breast
Authors: Nicolai Maass
Özkan Alkasi
Maret Bauer
Walter Jonat
R. Souchon
Ivo Meinhold-Heerlein
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 5/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-0999-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Actual management of ductal carcinoma in situ of the breast

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Management of a pregnancy complicated by yolk sac tumor

Genital tract tuberculosis among infertile women: an old problem revisited

Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation

Case report of a sarcoma botryoides of the uterine cervix in fertile age and literature review

Gitelman syndrome during pregnancy: a therapeutic challenge

Caffeine in pregnancy